**Additional file 1**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **IVIG responsiveness (N=108)** | **IVIG resistance (N=21)** | **Total (N=129)** | **p-value** |
| **Day of illness when treatment was given** |  |  |  | 0.490 |
| ≤4  | 10 (9.3%) | 4 (19.0%) | 14 (10.9%) |  |
| 5-10 | 82 (75.9%) | 15 (71.4%) | 97 (75.2%) |  |
| ≥10 | 15 (13.9%) | 2 (9.5%) | 17 (13.2%) |  |
| **Alb before treatment** |  |  |  | <0.001 |
| ≤ 3.2mg/dl | 15 (13.9%) | 14 (66.7%) | 29 (22.5%) |  |
| >3.2 mg/dl | 63 (58.3%) | 5 (23.8%) | 68 (52.7%) |  |
| **ESR before treatment** |  |  |  | 1.000 |
| >75mm/hr | 48 (44.4%) | 9 (42.9%) | 57 (44.2%) |  |
| ≤75mm/hr | 57 (52.8%) | 12 (57.1%) | 69 (53.5%) |  |
| **Hb before treatment**  |  |  |  | 0.278 |
| <10.2 g/dL | 43 (39.8%) | 11 (52.4%) | 54 (41.9%) |  |
| ≥10.2 g/dL | 53 (49.1%) | 10 (47.6%) | 63 (48.8%) |  |
| **Neu% before treatment** |  |  |  | 0.080 |
| ≥80% | 21 (19.4%) | 9 (42.9%) | 30 (23.3%) |  |
| <80% | 85 (78.7%) | 12 (57.1%) | 97 (75.2%) |  |
| **Platelets before treatment**  |  |  |  | 0.523 |
| ≤300 | 27 (25.0%) | 7 (33.3%) | 34 (26.4%) |  |
| >300 | 80 (74.1%) | 14 (66.7%) | 94 (72.9%) |  |
| **ALT before treatment** |  |  |  | 0.030 |
| ≥80 U/L | 33 (30.6%) | 13 (61.9%) | 46 (35.7%) |  |
| <80 U/L | 73 (67.6%) | 8 (38.1%) | 81 (62.8%) |  |
| **AST before treatment**  |  |  |  | 0.135 |
| ≥100 U/L | 17 (15.7%) | 7 (33.3%) | 24 (18.6%) |  |
| <100 U/L | 80 (82.4%) | 14 (66.7%) | 103 (79.8%) |  |
| **Sodium before treatment** |  |  |  | 0.043 |
| ≤133 mmol/L | 30 (27.8%) | 12 (57.1%) | 42 (32.6%) |  |
| >134 mmol/L | 74 (68.5%) | 9 (42.9%) | 83 (64.3%) |  |
| **Age**  |  |  |  | 0.205 |
| <6 months | 9 (8.3%) | 3 (14.3%) | 12 (9.3%) |  |
| 6-12 months | 16 (14.8%) | 0 (0.0%) | 16(12.4%) |  |
| 12-59 months | 65 (60.2%) | 14 (66.7%) | 79 (61.2%) |  |
| >60 months | 18 (16.7%) | 4 (19.0%) | 22 (17.1%) |  |
| **Sex**  |  |  |  | 0.340 |
| Female | 50 (46.3%) | 7 (33.3%) | 57 (44.2%) |  |
| Male | 58 (53.7%) | 14 (66.7%) | 72 (55.8%) |  |